• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Gold Moves Lower; ISM Services PMI Beats Estimates

    2/5/24 12:08:40 PM ET
    $CHEA
    $DMK
    $EVBG
    $FDMT
    Blank Checks
    Finance
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CHEA alert in real time by email

    U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling more than 100 points on Monday.

    The Dow traded down 1.04% to 38,253.72 while the NASDAQ fell 0.86% to 15,493.97. The S&P 500 also fell, dropping, 0.70% to 4,923.81.

    Check This Out: Pinterest To Rally Over 20%? Here Are 10 Top Analyst Forecasts For Monday

     

    Leading and Lagging Sectors

     

    Health care shares rose by 0.4% on Monday.

    In trading on Monday, materials shares fell by 2.6%.

     

    Top Headline

     

    The ISM services PMI for the US rose to 53.4 in January versus 50.5 in the prior month, and topping market estimates of 52.

     

    Equities Trading UP

     

    Everbridge, Inc. (NASDAQ:EVBG) shares shot up 18% to $28.12 after the company announced it will be acquired by Thoma Bravo for $1.5 billion.

    Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) got a boost, surging 73% to $30.30 after the company announced interim data from the Phase 2 PRISM clinical trial evaluating intravitreal 4D-150 in wet AMD patients with severe disease activity and a high treatment burden.

    Chenghe Acquisition Co. (NASDAQ:CHEA) shares were also up, gaining 63% to $8.97 after shareholders on Friday voted to approve the merger agreement with Taiwan Color Optics.

     

    Equities Trading DOWN

     

    NanoString Technologies, Inc. (NASDAQ:NSTG) shares dropped 73% to $0.1283 after the company initiated voluntary Chapter 11 restructuring proceedings.

    Shares of DMK Pharmaceuticals Corporation (NASDAQ:DMK) were down 52% to $0.2484. The company filed voluntary petitions under Chapter 11 of the U.S. Bankruptcy Code in the United States Bankruptcy Court for the District of Delaware.

    Pineapple Energy Inc. (NASDAQ:PEGY) was down, falling 45% to $0.2511 after the company priced a $1 million registered direct offering of common stock.

    Also Check This Out: How To Earn $500 A Month From Eli Lilly Stock Ahead Of Q4 Earnings Report

     

    Commodities

     

    In commodity news, oil traded down 0.1% to $72.23 while gold traded down 0.9% at $2,034.30.

    Silver traded down 1.7% to $22.405 on Monday while copper fell 1.3% to $3.7725.

     

    Euro zone

     

    European shares were mostly lower today. The eurozone’s STOXX 600 fell 0.11%, London’s FTSE 100 fell 0.08% while Spain’s IBEX 35 Index fell 1.1% The German DAX fell 0.18% French CAC 40 fell 0.26% while Italy’s FTSE MIB Index rose 0.60%.

    The HCOB Eurozone services PMI declined to 48.4 in January versus 48.8 in the prior month, while composite PMI surged to a six-month high of 47.9 in January. The HCOB Germany Services PMI rose to 47.7 in January versus a preliminary reading of 47.6, while France services PMI was revised higher to 45.4 in January compared to a preliminary level of 45.

    New car registrations in the UK rose by 8.2% year-over-year to 142,876 units in January. The United Kingdom's unemployment rate fell to 3.9% during the three months leading up to November.

     

    Asia Pacific Markets

     

    Asian markets closed mostly lower on Monday, with Japan’s Nikkei 225 gaining 0.54%, Hong Kong’s Hang Seng Index falling 0.15% and China’s Shanghai Composite Index falling 1.02%. India’s S&P BSE Sensex, meanwhile, fell 0.49%.

    The HSBC India services PMI rose to 61.8 in January compared to a preliminary reading of 61.2. The Caixin China General service PMI fell to 52.7 in January compared to December’s reading of 52.9.

    The S&P Global Hong Kong SAR PMI declined to 49.9 in January versus 51.3 in December. The au Jibun Bank Japan services PMI rose to 53.1 in January compared to a preliminary reading of 52.7.

     

    Economics

     

    The S&P Global US services PMI was revised lower to 52.5 in January compared to the preliminary reading of 52.9.

    The S&P Global US Composite PMI slipped to 52.0 in January, versus the preliminary reading of 52.3.

    The ISM services PMI for the US rose to 53.4 in January versus 50.5 in the prior month, and topping market estimates of 52.

    Now Read This: Top 5 Consumer Stocks That Could Blast Off In Q1

     

    Get the next $CHEA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CHEA
    $DMK
    $EVBG
    $FDMT

    CompanyDatePrice TargetRatingAnalyst
    4D Molecular Therapeutics Inc.
    $FDMT
    1/28/2026$33.00Overweight
    Barclays
    4D Molecular Therapeutics Inc.
    $FDMT
    11/7/2025Underweight → Equal-Weight
    Morgan Stanley
    4D Molecular Therapeutics Inc.
    $FDMT
    1/13/2025$40.00 → $15.00Outperform → Market Perform
    BMO Capital Markets
    4D Molecular Therapeutics Inc.
    $FDMT
    11/21/2024$8.00Underweight
    Morgan Stanley
    4D Molecular Therapeutics Inc.
    $FDMT
    9/23/2024Overweight → Neutral
    Cantor Fitzgerald
    4D Molecular Therapeutics Inc.
    $FDMT
    4/15/2024$45.00Overweight
    Barclays
    4D Molecular Therapeutics Inc.
    $FDMT
    4/15/2024$459.00Overweight
    Barclays
    4D Molecular Therapeutics Inc.
    $FDMT
    2/7/2024$81.00Buy
    Goldman
    More analyst ratings

    $CHEA
    $DMK
    $EVBG
    $FDMT
    SEC Filings

    View All

    4D Molecular Therapeutics Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities, Financial Statements and Exhibits

    8-K - 4D Molecular Therapeutics, Inc. (0001650648) (Filer)

    1/26/26 4:05:26 PM ET
    $FDMT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    4D Molecular Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Leadership Update

    8-K - 4D Molecular Therapeutics, Inc. (0001650648) (Filer)

    1/7/26 8:05:25 AM ET
    $FDMT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    4D Molecular Therapeutics Inc. filed SEC Form 8-K: Other Events

    8-K - 4D Molecular Therapeutics, Inc. (0001650648) (Filer)

    12/10/25 4:06:12 PM ET
    $FDMT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CHEA
    $DMK
    $EVBG
    $FDMT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Conroy Jeffrey J. bought $40,331 worth of shares (350,704 units at $0.11) and sold $1,810 worth of shares (16,014 units at $0.11), increasing direct ownership by 18% to 2,194,690 units (SEC Form 4)

    4 - Pineapple Energy Inc. (0000022701) (Issuer)

    10/15/24 9:50:04 PM ET
    $PEGY
    Telecommunications Equipment
    Utilities

    Large owner Conroy Jeffrey J. bought $36,063 worth of shares (333,921 units at $0.11) and sold $3,133 worth of shares (29,010 units at $0.11), increasing direct ownership by 20% to 1,860,000 units (SEC Form 4)

    4 - Pineapple Energy Inc. (0000022701) (Issuer)

    10/11/24 9:52:05 PM ET
    $PEGY
    Telecommunications Equipment
    Utilities

    Director Holland Tom bought $3,915 worth of shares (3,000 units at $1.30), increasing direct ownership by 149% to 5,012 units (SEC Form 4)

    4 - Pineapple Energy Inc. (0000022701) (Issuer)

    6/17/24 4:20:07 PM ET
    $PEGY
    Telecommunications Equipment
    Utilities

    $CHEA
    $DMK
    $EVBG
    $FDMT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Barclays resumed coverage on 4D Molecular Therapeutics with a new price target

    Barclays resumed coverage of 4D Molecular Therapeutics with a rating of Overweight and set a new price target of $33.00

    1/28/26 7:14:57 AM ET
    $FDMT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    4D Molecular Therapeutics upgraded by Morgan Stanley

    Morgan Stanley upgraded 4D Molecular Therapeutics from Underweight to Equal-Weight

    11/7/25 8:04:44 AM ET
    $FDMT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    4D Molecular Therapeutics downgraded by BMO Capital Markets with a new price target

    BMO Capital Markets downgraded 4D Molecular Therapeutics from Outperform to Market Perform and set a new price target of $15.00 from $40.00 previously

    1/13/25 7:43:59 AM ET
    $FDMT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CHEA
    $DMK
    $EVBG
    $FDMT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Sblendorio Glenn

    4 - 4D Molecular Therapeutics, Inc. (0001650648) (Issuer)

    1/7/26 9:12:50 PM ET
    $FDMT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 3 filed by new insider Sblendorio Glenn

    3 - 4D Molecular Therapeutics, Inc. (0001650648) (Issuer)

    1/7/26 9:10:20 PM ET
    $FDMT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    VP, Finance and Controller Gupta Ashoo converted options into 1,086 shares and sold $3,377 worth of shares (389 units at $8.68), increasing direct ownership by 2% to 46,359 units (SEC Form 4)

    4 - 4D Molecular Therapeutics, Inc. (0001650648) (Issuer)

    12/23/25 9:05:45 PM ET
    $FDMT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CHEA
    $DMK
    $EVBG
    $FDMT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    4DMT Announces New Employment Inducement Grants

    EMERYVILLE, Calif., Jan. 17, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (NASDAQ:FDMT, 4DMT or the Company)), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that on January 13, 2026, the compensation committee of the Company's board of directors granted four new non-executive employees 23,600 Restricted Stock Units (RSUs). The RSUs were granted pursuant to the Company's 2025 Employment Inducement Award Plan, which was approved by the Company's board of directors in February 2025 under Rule 5635(c)(4) of The Nasdaq Global Mark

    1/17/26 8:00:51 AM ET
    $FDMT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    4DMT Provides Company Update and Anticipated Development Milestones for 2026

    Enrollment in 4D-150 Phase 3 wet AMD clinical trials exceeding expectations; 4FRONT-1 trial remains on track to complete enrollment in Q1 2026, with 381 patients randomized or approved to randomize as of January 6, 20264D-150 PRISM wet AMD 2-year Phase 2b data expected mid-20264D-150 DME global Phase 3 trial initiation expected Q3 2026; 2-year SPECTRA Phase 1/2 data expected H2 2026Appointed Glenn Sblendorio to Board of Directors, adding deep commercial and operating experience, including in retina therapeuticsCompany to present strategic outlook at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, at 7:30am PT EMERYVILLE, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) -

    1/7/26 8:00:00 AM ET
    $FDMT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    4DMT Announces Positive Interim Clinical Data from 4D-710 AEROW Phase 1 Clinical Trial in Cystic Fibrosis Lung Disease

    Clinically meaningful lung function activity, measured by ppFEV1 and LCI2.5, with follow-up through 1 year at dose selected for Phase 2 Durable CFTR transgene expression within target therapeutic range with follow-up through at least 1 year Data support 4D-710's potential to be a durable, redosable, variant-agnostic, disease-modifying treatment for people with cystic fibrosis lung disease with high unmet needWebcast today at 8:00 a.m. ET with distinguished cystic fibrosis KOLs EMERYVILLE, Calif., Dec. 17, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (NASDAQ:FDMT, 4DMT, or the Company)), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics wi

    12/17/25 7:00:00 AM ET
    $FDMT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CHEA
    $DMK
    $EVBG
    $FDMT
    Leadership Updates

    Live Leadership Updates

    View All

    NovaBridge's Visara Subsidiary Appoints Distinguished Ophthalmology Leaders as Chief Medical Officer and Scientific Advisory Board Chair to Drive VIS-101 Forward

    Cadmus C. Rich, MD, MBA, as Chief Medical Officer, and Carlos Quezada-Ruiz, MD, FASRS, as Chair of the Scientific Advisory Board, bring invaluable clinical development expertise to VIS-101 ProgramThe ability to attract seasoned ophthalmology leaders highlights the compelling opportunity for VIS-101, and underscores our commitment to assembling a world-class teamVIS-101, a novel bifunctional biologic targeting VEGF-A/ANG2, has the potential to become the current standard for wet AMD, DME and RVO, and is expected to be Phase-3-ready in 2026 ROCKVILLE, Md., Nov. 20, 2025 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (NASDAQ:NBP) (NovaBridge or the Company) a global biotechnology platform compa

    11/20/25 8:00:00 PM ET
    $AURA
    $FDMT
    $NBP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    4DMT Appoints Kristian Humer as Chief Financial Officer

    EMERYVILLE, Calif., Nov. 17, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (NASDAQ:FDMT, 4DMT or the Company)), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced the appointment of Kristian Humer as Chief Financial Officer. Mr. Humer will lead the Company's financial strategy and operations, including responsibility for financial planning, capital allocation, corporate development and supporting strategic initiatives. Mr. Humer is an accomplished finance executive and biotechnology leader with more than two decades of experience

    11/17/25 6:00:00 AM ET
    $FDMT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    4DMT Announces Leadership Expansion with Proven Late-Stage Executives to Drive 4D-150 Execution and BLA Readiness

    Julie Clark, M.D., promoted to Chief Medical Officer Liansheng Zhu, Ph.D., joined as SVP, Biometrics and Data Quality4FRONT-1 Phase 3 trial enrollment continues to exceed expectations, with enrollment completion now expected in Q1 2026 Addition of distinguished retina industry advisors enhances global development and commercialization expertise EMERYVILLE, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (NASDAQ:FDMT, 4DMT or the Company)), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced senior leadership additi

    9/2/25 8:00:00 AM ET
    $FDMT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CHEA
    $DMK
    $EVBG
    $FDMT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by 4D Molecular Therapeutics Inc.

    SC 13G/A - 4D Molecular Therapeutics, Inc. (0001650648) (Subject)

    11/15/24 5:05:27 PM ET
    $FDMT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by 4D Molecular Therapeutics Inc.

    SC 13G/A - 4D Molecular Therapeutics, Inc. (0001650648) (Subject)

    11/14/24 5:46:12 PM ET
    $FDMT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by 4D Molecular Therapeutics Inc.

    SC 13G/A - 4D Molecular Therapeutics, Inc. (0001650648) (Subject)

    11/14/24 4:31:18 PM ET
    $FDMT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CHEA
    $DMK
    $EVBG
    $FDMT
    Financials

    Live finance-specific insights

    View All

    Pineapple Energy Reports First Quarter 2024 Financial Results

    First Quarter 2024: Revenue down 40% from Q1 2023Gross profit down 40% from Q1 2023Operating Expenses down 31% from Q1 2023Operating Loss increased 2% from Q1 2023Net Income of $1.2M, Net Loss attributable to common shareholders of $10.1MAdjusted EBITDA loss of $1.5M MINNETONKA, Minn., May 09, 2024 (GLOBE NEWSWIRE) -- Pineapple Energy Inc. (NASDAQ:PEGY), a leading provider of sustainable solar energy and back-up power to households and small businesses, today announced financial results for the first quarter ended March 31, 2024. Pineapple CEO Kyle Udseth commented, "The first quarter of 2024 presented the toughest operating conditions we've faced in our time as a public company. Negati

    5/9/24 4:15:00 PM ET
    $PEGY
    Telecommunications Equipment
    Utilities

    Everbridge Announces First Quarter 2024 Financial Results

    Everbridge, Inc. (NASDAQ:EVBG), the global leader in critical event management (CEM) and national public warning solutions, today announced its financial results for the first quarter ended March 31, 2024. Revenue for the first quarter was up 3% year-over-year to $111.4 million, and GAAP net loss was $(20.1) million, compared to $(14.6) million for the first quarter of 2023. First Quarter 2024 Financial Highlights Total revenue was $111.4 million, an increase of 3% compared to $108.3 million for the first quarter of 2023. Revenue from subscription services was $105.3 million, an increase of 7% compared to $98.8 million for the first quarter of 2023. Revenue from professional services,

    5/9/24 4:01:00 PM ET
    $EVBG
    Computer Software: Prepackaged Software
    Technology

    Pineapple Energy to Release First Quarter 2024 Results, Host Conference Call on May 10

    MINNETONKA, Minn., May 06, 2024 (GLOBE NEWSWIRE) -- Pineapple Energy Inc. (NASDAQ:PEGY), a leading provider of sustainable solar energy and back-up power to households and small businesses, today announced that management will host a conference call for investors and analysts on Friday, May 10 at 8:30am ET to discuss the company's first quarter 2024 financial results. The company plans to provide a press release reporting its results on the Investor Relations section of its website at https://ir.pineappleenergy.com/news-events after the close of the financial markets on May 9, 2024 prior to the conference call. About Pineapple EnergyPineapple is focused on growing leading local and region

    5/6/24 4:33:33 PM ET
    $PEGY
    Telecommunications Equipment
    Utilities